Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 4/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.44 |
| ▸ | ORAI2 | Q96SN7 | 3/20 | 0.44 |
| ▸ | ORAI3 | Q9BRQ5 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556708 | 0.82 | PPARG (0.40) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL13857958 | 0.81 | TRPV6 (0.35) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL1276215 | 0.78 | CA1 (0.43) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL29140215 | 0.78 | CA1 (0.43) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| Boric Acid SCHEMBL10871300 | 0.76 | CA1 (0.41) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL1408264 | 0.76 | CA1 (0.41) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL2475622 | 0.76 | ORAI1 (0.48) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL28718291 | 0.75 | TRPV6 (0.52) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL262207 | 0.74 | ENPP2 (0.46) | TRPV6ORAI1ORAI2ORAI3CA4 | |
| SCHEMBL29192896 | 0.74 | ORAI1 (0.38) | TRPV6ORAI1ORAI2ORAI3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425510-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.P.A. (IT) | 2024-12-26 | — | — | US | claimed |
| CN-118878402-A | Preparation method of trifluoromethyl ketone compound based on palladium catalysis of C-N bond cleavage | 大连理工大学 | 2024-11-01 | — | — | CN | claimed |
| EP-4416149-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.p.A. (IT) | 2024-08-21 | — | — | EP | claimed |
| CN-117865773-A | Preparation method of difluoromethyl aromatic compound based on palladium-catalyzed decarbonylation coupling | 大连理工大学 | 2024-04-12 | — | — | CN | claimed |
| WO-2023062504-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.P.A. (IT) | 2023-04-20 | — | — | WO | claimed |
| US-20240425510-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.P.A. (IT) | 2024-12-26 | — | — | US | disclosed |
| CN-118878402-A | Preparation method of trifluoromethyl ketone compound based on palladium catalysis of C-N bond cleavage | 大连理工大学 | 2024-11-01 | — | — | CN | disclosed |
| EP-4416149-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.p.A. (IT) | 2024-08-21 | — | — | EP | disclosed |
| CN-117865773-A | Preparation method of difluoromethyl aromatic compound based on palladium-catalyzed decarbonylation coupling | 大连理工大学 | 2024-04-12 | — | — | CN | disclosed |
| US-11883387-B2 | PqsR inverse agonists | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-01-30 | — | — | US | disclosed |
| WO-2023062504-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.P.A. (IT) | 2023-04-20 | — | — | WO | disclosed |
| WO-2021236681-A2 | POTENT TETRAHYDROQUINOLONE ELIMINATES APICOMPLEXAN PARASITES | THE UNIVERSITY OF CHICAGO (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2012020848-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100087646-A1 | REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-08 | — | — | US | disclosed |
| WO-2009066060-A2 | 4-SUBSTITUTED-6-ISOPROPYL-BENZENE-1,3-DIOL COMPOUNDS AND THEIR USE | TOPOTARGET A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
| WO-2008021960-A2 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040082627-A1 | Certain aromatic monocycles as kinase modulators | CGI PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425510-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | BCL6B, BCL6, BCL9 | TRPV6 4817/4885ORAI1 4294/4885ORAI2 3537/4885 |
| US-20040082627-A1 | Certain aromatic monocycles as kinase modulators | MAP3K20, MAP3K1, MAP3K19 | TRPV6 1188/4885ORAI1 2731/4885ORAI2 3322/4885 |
| US-11883387-B2 | PqsR inverse agonists | QRFPR, P2RY11, QARS1 | TRPV6 1202/4885ORAI1 951/4885ORAI2 1216/4885 |
| US-20100087646-A1 | REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT | ORC3, OXSR1, OSTC | TRPV6 119/4885ORAI1 788/4885ORAI2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.